Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.
Schmalzing MarcHerbert KellnerAyman AskariJavier De Toro SantosJulio Cesar Vazquez Perez-ColemanRosario FotiSławomir JekaBoulos HaraouiYannick AllanorePeter PeichlMartin OehriMasiur RahmanFabricio FurlanElisa RomeroSohaib HachaichiCharlotte BothInes BrueckmannTom SheeranPublished in: Advances in therapy (2023)
These results support the effectiveness and safety of SDZ ETN treatment in patients with RA, axSpA or PsA in real-life conditions. The treatment persistence rates observed were consistent with previously published reports of patients treated with reference or other biosimilar ETN. No new safety signals were identified.